 - Patients with primary refractory AML that is no prior remission. Patients who have greater than 10 AML blasts in the bone marrow or blood upon recovery from two cycles of standard cytarabine- and anthracycline-based induction chemotherapy are eligible. Patients who have received etoposide andor 6-thioguanine during remission induction will be eligible. 